ACRS - Aclaris to meet competition from Incyte in atopic dermatitis

Yesterday, Aclaris Therapeutics ([[ACRS]] -8.4%) announced positive data from a Phase 2a study for its JAK inhibitor ATI-1777 in patients with moderate to severe atopic dermatitis ((AD)).The study achieved statistical significance with the primary endpoint of modified Eczema Area and Severity Index ((mEASI)) score indicating a 74.4% reduction at week four compared to a 41.4% reduction in subjects applying vehicle.However, Aclaris is likely to meet strong competition from Incyte and Lilly which are anticipating an FDA decision on their AD candidate. The PDUFA action date is estimated for early Q3.In TRuE-AD Phase 3 trials, compared to 7.7% with vehicle cream, three-quarters of patients showed 75% improvement from baseline in the Eczema Area and Severity Index in response to the investigational JAK1/JAK2 inhibitor ruxolitinib cream 0.75%.Encouraged by the strength of mid-stage data, Aclaris has announced a fundraising attempt targeting to sell $75 million in shares.

For further details see:

Aclaris to meet competition from Incyte in atopic dermatitis